LB Pharmaceuticals, Inc.
Pioneering advancements in CNS treatment by bringing overseas innovations to the U.S. market through dedicated research and improved drug versions.
Pioneering advancements in CNS treatment by bringing overseas innovations to the U.S. market through dedicated research and improved drug versions.
LB Pharmaceuticals, Inc. is a pioneering life sciences company founded in 2015. The company focuses on revolutionizing CNS treatment by introducing innovative and improved versions of successful therapies from overseas to the U.S. market. Its mission is to develop and market therapies widely used abroad but not yet available in the United States. LB Pharmaceuticals creates a research-driven environment to generate new intellectual property related to these once-leading medications. The latest investment of $75.00M in Series C funding, led by Pontifax in 24 January 2024, demonstrates the growing interest and confidence from investors in the company's unique approach to CNS treatment. With a focus on biopharma, biotechnology, and pharmaceuticals, LB Pharmaceuticals is poised to make a significant impact on the U.S. healthcare market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $75.00M | 1 |
|
24 Jan 2024 |
| Venture Round | $40.00M | - | 26 Sep 2023 | |
| Series B | $10.00M | - | 25 Sep 2020 | |
| Venture Round | $6.33M | - | 21 Nov 2018 | |
| Seed Round | $443.20K | - | 20 Dec 2017 |
No recent news or press coverage available for LB Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
